0JQ2 Stock Chart & Stats
$0.70
$0.07(10.35%)
At close: 4:00 PM EDT
$0.70
$0.07(10.35%)
Day’s Range― - ―
52-Week Range$0.59 - $1,028.55
Previous CloseN/A
Volume2.44K
Average Volume (3M)23.35K
Market Cap
$13.35M
Enterprise Value-$7.10
Total Cash (Recent Filing)$7.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,339,787
10 Day Avg. Volume15,826
30 Day Avg. Volume23,354
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetEliminating debt reduces interest obligations, refinancing needs, and leverage-related risk. Positive equity also provides a stronger structural position than prior years, although the limited asset base still leaves little protection if operating losses continue.
Reduced Net LossA smaller loss indicates some improvement in cost control or operating efficiency compared with earlier periods. This is a modest positive for longer-term viability, but it has not yet translated into revenue growth, operating profitability, or financial independence.
Improving Cash Burn TrendThe reduction in annual cash burn suggests spending has become more disciplined than in 2025, potentially extending the company’s operating runway. However, cash flow remains materially negative, so this improvement does not remove the need for future financing.
Bears Say
No Meaningful Revenue BaseNear-zero revenue means the company lacks recurring operating income to support research, development, and corporate costs. Without a commercial revenue base, future progress remains dependent on successful product development and access to external capital.
Persistent Cash ConsumptionSustained negative cash generation weakens liquidity and creates continuing dependence on financing. Even with burn improving from 2025, the absence of revenue means the company may need additional capital to maintain operations and fund its pipeline.
Nasdaq Listing UncertaintyPotential suspension or delisting could reduce trading liquidity, institutional participation, and access to public-market financing. The hearing temporarily stays enforcement, but the unresolved compliance issue adds a durable regulatory and funding risk.
KALA BIO News
0JQ2 FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest share price was $0.59 and its highest was $1028.55 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $13.35M.
When is KALA BIO’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were KALA BIO’s earnings last quarter?
Currently, no data Available
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on KALA BIO dividends here
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 19,339,787 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in GB:0JQ2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Citius Pharmaceuticals
―
Lexaria Bioscience
―
Exicure
―